Pathology & Oncology Research

, Volume 25, Issue 1, pp 421–427 | Cite as

Association Between Polymorphisms in the Promoter Region of microRNA-34b/c and the Chemoradiotherapy Efficacy for Locally Advanced Esophageal Squamous Cell Carcinoma in Chinese Han Population

  • Jilisihan Bulibu
  • Wei Wang
  • Yong Tang
  • Na Li
  • Keyoumu SaifudingEmail author
Original Article


The study aims to explore the association between polymorphisms in the promoter region of microRNA-34b/c (miR-34b/c) and the chemoradiotherapy efficacy for locally advanced esophageal squamous cell carcinoma (ESCC) in Chinese Han population. A total of 175 locally advanced ESCC cases and 186 healthy individuals were enrolled as the case and control groups. Denaturing high performance liquid chromatography (DHPLC) was applied to determine the genotypes of subjects. Subjects in the case group were classified into complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). CR + PR were defined as the sensitive group, and SD + PD were defined as the resistance group. All patients were followed up for 3 ~ 36 months. Receiver operating characteristic (ROC) curve was used to evaluate the predictive value of rs4938723 in the promoter region of miR-34b/c in the chemoradiotherapy efficacy for patients with locally advanced ESCC. The distribution of genotype and allele of rs4938723 in the promoter region of miR-34b/c was significantly different between the case and control group (both P < 0.05), and CC genotype and C allele could decrease the risk of ESCC (CC genotype: OR = 0.57, 95%CI = 0.32 ~ 0.99, P = 0.045; C allele: OR = 0.72, 95%CI = 0.54 ~ 0.97, P = 0.032). MiR-34b/c rs4938723 was associated with ESCC TNM staging, differentiation degree, and lymph node metastasis (LNM) for ES CC patients (all P < 0.05). The chemoradiotherapy efficacy of patients with CC genotype was better than that of patients with (TT + TC) genotypes (P < 0.05). ROC curve results showed that the area under curve (AUC), sensitivity and specificity were 0.777, 85.1% and 71.3%, respectively. The average median progression free survival (PFS) of patients with (TT + TC) genotypes was significantly shorter than those patients with CC genotype (P < 0.05). Our study provides evidence that miR-34b/c rs4938723 is closely related with the chemoradiotherapy efficacy for locally advanced ESCC.


MicroRNA-34b/c Esophageal squamous cell carcinoma Promoter region Polymorphism Chemoradiotherapy efficacy Chinese Han population 



We would like to thank all the people for their technical assistance and valuable advice.

Author Contribution

JB and YT designed the study. WW and KS collated the data, designed and developed the database, carried out data analyses and produced the initial draft of the manuscript. NL contributed to drafting the manuscript. All authors have read and approved the final submitted manuscript.

Compliance with Ethical Standards

Conflict of Interest



  1. 1.
    Chen J, Kwong DL, Cao T, Hu Q, Zhang L, Ming X, Chen J, Fu L, Guan X (2015) Esophageal squamous cell carcinoma (ESCC): advance in genomics and molecular genetics. Dis Esophagus 28:84–89CrossRefGoogle Scholar
  2. 2.
    Wu C, Hu Z, He Z, Jia W, Wang F, Zhou Y, Liu Z, Zhan Q, Liu Y, Yu D, Zhai K, Chang J, Qiao Y, Jin G, Liu Z, Shen Y, Guo C, Fu J, Miao X, Tan W, Shen H, Ke Y, Zeng Y, Wu T, Lin D (2011) Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet 43:679–684CrossRefGoogle Scholar
  3. 3.
    Zhang X, Li M, Meng X, Kong L, Zhang Y, Wei G, Zhang X, Shi F, Hu M, Zhang G, Yu J (2014) Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol 9:64CrossRefGoogle Scholar
  4. 4.
    Cho SH, Shim HJ, Lee SR, Ahn JS, Yang DH, Kim YK, Nam TK, Lee JJ, Kim HJ, Chung IJ (2008) Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Dis Esophagus 21:697–703CrossRefGoogle Scholar
  5. 5.
    Li DJ, Li HW, He B, Wang GM, Cai HF, Duan SM, Liu JJ, Zhang YJ, Cui Z, Jiang H (2016) Patterns of failure after involved field radiotherapy for locally advanced esophageal squamous cell carcinoma. J BUON 21:1268–1273Google Scholar
  6. 6.
    Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, Yoshida N, Toyama E, Hayashi N, Watanabe M, Baba H (2009) MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 15:1915–1922CrossRefGoogle Scholar
  7. 7.
    Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, Matsubara H (2010) miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127:2804–2814CrossRefGoogle Scholar
  8. 8.
    Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY (2007) MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67:8433–8438CrossRefGoogle Scholar
  9. 9.
    Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano HO, Yoshikawa K, Kimura T, Kudo T, Harada E, Sugai T, Takamaru H, Niinuma T, Maruyama R, Yamamoto H, Tokino T, Imai K, Toyota M, Shinomura Y (2010) Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis 31:2066–2073CrossRefGoogle Scholar
  10. 10.
    Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, Tokino T (2008) Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 68:4123–4132CrossRefGoogle Scholar
  11. 11.
    Lin Z, Chen L, Song M, Shi KQ, Tang KF (2014) Association between a polymorphism in miR-34b/c and susceptibility to cancer--a meta-analysis. Asian Pac J Cancer Prev 15:7251–7255CrossRefGoogle Scholar
  12. 12.
    Wang X, Lu X, Fang Y, Chen H, Deng X, Peng C, Li H, Shen B (2014) Association between miR34b/c polymorphism rs4938723 and cancer risk: a meta-analysis of 11 studies including 6169 cases and 6337 controls. Med Sci Monit 20:1977–1982CrossRefGoogle Scholar
  13. 13.
    Rice TW (2015) Esophageal cancer staging. Korean J Thorac Cardiovasc Surg 48:157–163CrossRefGoogle Scholar
  14. 14.
    Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y (2012) Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res 18:5144–5153CrossRefGoogle Scholar
  15. 15.
    Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, Li B, Meng X, Ma X, Luo M, Shao K, Li N, Qiu B, Mitchelson K, Cheng J, He J (2008) Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 68:26–33CrossRefGoogle Scholar
  16. 16.
    Ji TX, Zhi C, Guo XG, Zhou Q, Wang GQ, Chen B, Ma FF (2015) MiR-34b/c rs4938723 polymorphism significantly decreases the risk of digestive tract cancer: meta-analysis. Asian Pac J Cancer Prev 16:6099–6104CrossRefGoogle Scholar
  17. 17.
    Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, Liu S, Liu Z, Shi H, Shen H, Hu Z (2011) A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 128:412–417CrossRefGoogle Scholar
  18. 18.
    Wang Z, Wu J, Zhang G, Cao Y, Jiang C, Ding Y (2013) Associations of miR-499 and miR-34b/c polymorphisms with susceptibility to hepatocellular carcinoma: an evidence-based evaluation. Gastroenterol Res Pract 2013:719202Google Scholar
  19. 19.
    Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, Hwang SG, Kim NK (2013) Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene 524:156–160CrossRefGoogle Scholar
  20. 20.
    Yin J, Wang X, Zheng L, Shi Y, Wang L, Shao A, Tang W, Ding G, Liu C, Liu R, Chen S, Gu H (2013) Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PLoS One 8:e80570CrossRefGoogle Scholar
  21. 21.
    Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D, Fiorentino E, Cicero G, Bazan V, Russo A (2012) The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets 16(Suppl 2):S103–S109CrossRefGoogle Scholar
  22. 22.
    Hermeking H (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17:193–199CrossRefGoogle Scholar
  23. 23.
    Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E, Nagashima M, Takenoshita S, Yokota J, Harris CC (2008) Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 68:3193–3203CrossRefGoogle Scholar
  24. 24.
    Cho CY, Huang JS, Shiah SG, Chung SY, Lay JD, Yang YY, Lai GM, Cheng AL, Chen LT, Chuang SE (2016) Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells. RNA 22:303–315CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2017

Authors and Affiliations

  • Jilisihan Bulibu
    • 1
  • Wei Wang
    • 1
  • Yong Tang
    • 1
  • Na Li
    • 1
  • Keyoumu Saifuding
    • 1
    Email author
  1. 1.Department of GastroenterologyThe Affiliated Tumor Hospital of Xinjiang Medical UniversityUrumqiPeople’s Republic of China

Personalised recommendations